Search Results
Results found for "Chun-Chun Chang"
- The One Reason Why Biotech Startups Fail More Often Than They Should
This article examines why biotech startups fail when strategy is absent , and how that outcome can be changed are stopped 2ď¸âŁ Milestones exist, but they do not unlock real decisions 3ď¸âŁ Data accumulates without changing Additional data feels like risk reduction, even when it does not change the strategic picture. Leadership understands what outcome would trigger a change in direction. â The goal is not certainty. Designing order also changes how teams experience pressure.
- Dynamic GPCR activation revealed through time-resolved Cryo-EM
These receptors respond to a variety of signals by undergoing structural changes that activate internal brief sequential intervals following GTP addition, the research team identified the conformational changes The captured structures reveal a dynamic of conformational changes initiated by the binding of an agonist This early interaction sets the stage for a cascade of significant conformational changes. Concurrently, the Îą1 helix extends, propagating structural changes throughout the G protein.
- Understanding Biased Signaling in GPCRs
AMA will discuss how these formats diverge, particularly for allosteric ligands, where efficacy can change Allosteric modulators can alter signaling efficacy without changing ligand affinity, uncoupling binding It's the kind of clarity that changes how you read your own data.
- Allosteric Binding Data Interpretation in Complex Receptor Systems
The consequences for assay interpretation are direct: Observed affinity changes reflect altered receptor In contrast, the same curve in an allosteric system reflects a progressive change in receptor affinity implications: Curve shape alone cannot diagnose mechanism Rightward shifts do not imply competition Affinity changes Mechanistically: The allosteric ligand imposes a finite change in affinity (cooperativity constraint)
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
Kenakinâs latest lecture delivers a game-changing framework for teams grappling with the gap between This lecture is a guide to understanding why intracellular drug access changes everything: from target scaffold permeability using modern, cost-effective pharmacokinetic assays  Why Intracellular GPCR Drugs Change
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
lanthanide probes, the team realized they could tune these molecules to become exquisitely sensitive to pH changes : Endogenous GLP-1 internalization shown in beta cells đ 2025: Revvity launches pHSense A Day That Changed questions about constitutive activity, agonist-induced internalization, and cellular dynamics. đ What Changed
- Is Your Agonist Really âWorkingââOr Are You Just Seeing What Your System Allows?
In this eye-opening module, Terry Kenakin explores a concept that could change how you interpret pharmacological
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
How two-stage GPCR binding creates âhighâ and âlowâ affinity states What temporal kinetics quietly change Changing tracer concentration moves the displacement curve. Changing receptor expression or G protein levels does not  remove curve heterogeneity. Non-specific binding control:  Adsorption to surfaces changes free ligand concentration.
- Understanding Orthosteric Binding: The Key to Drug Action
. đ Whether you're new to pharmacology or brushing up on basics, this lesson will change how you think The receptor may change shape upon binding, affecting how the drug interacts and how effective it will
- Decoding GPCR Function: The Role of Mutagenesis in Rational Drug Discovery
Mutagenesis involves deliberately altering the DNA sequence of a gene to study the resulting changes framework that combined mutagenesis and structural data to contextualise ligand-induced structural changes datasets, allowing researchers to determine the functional consequences of every possible amino acid change ligand-receptor interactions, mutagenesis fills crucial knowledge gaps by revealing how specific amino acid changes B., Chang, B., & Peisajovich, S. G. (2017).
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
Allostery and Biased Signaling Change the Game The most profound change in GPCR drug discovery is our discovery teams, pharmacologists refining core skills, and R&D leads who need clear reasoning in a rapidly changing
- Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift
In environments where the plan changes often, usefulness becomes the multiplier. Usefulness reveals itself only under pressure. â Recognizing this difference changes how founders evaluate It also changes what questions matter when building the team. despite missing information. 2ď¸âŁ How they react to shifting priorities: Ask about situations where plans changed
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
Allosteric sites operate differently: ligands bind elsewhere, transmit energy changes, and shift the How Conformational Changes Drive Affinity and Efficacy A key takeaway from this session: affinity and Thatâs where Terryâs Corner changes the game.
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
neuromodulator, neurotransmitter, etc.), binds to the extracellular binding site of the GPCR, the protein changes the β2 adrenergic receptor (β2AR; PDB ID: 2RH1); (B) A ligand-bound GPCR undergoes a conformational change The conformation change induced by the agonist may not always lead to the same intracellular signaling
- Glyco-sulfo hotspots in the chemokine receptor system
extracellular loops and transmembrane domains of the receptor (CRS2), which will trigger conformational changes N-terminal region of chemokine receptors is indispensable for chemokine binding, where the negatively charged residues, as a consequence of the negatively charged aminoacids and post-translational modifications (PTMs), contribute to the high affinity binding to the positively charged groove on the chemokine. N-terminal PTMs include sulfation and glycosylation which contribute to the overall negative charge of
- GPCR Collaboration: From Models to Medicine
That perspective changed the moment he entered GPCR research . That candor changes the tone of collaboration . Pharmacologists know they arenât being oversold. It also allows Carlsson to stay plugged into the fast-changing needs of biotech while keeping his academic
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
is like adjusting the brightness on a microscopeâset it right, and hidden details jump into focus, changing Can changing receptor density predict how your drug will behave across sensitive versus less sensitive Thatâs where Terryâs Corner  changes the game.
- How Collaboration Drives GPCR Discoveries
They start with a chance email, an unexpected visitor at the door, or the moment a team realizes the That changed when JBâs team walked in with a different lens.
- From Pipettes to Platforms: The Evolution of GPCR Research
What Changed After This : High-throughput capabilities meant researchers could map GPCR signaling more But the heart of the field hasnât changed.
- The Chemistry of Confidence: Aha Moments That Shape Scientific Careers
âThe first time I wore my lucky cactus shirt to a major meeting... and it led to a game-changing collaboration
- The Hidden Burn: How Internal Misalignment Drains Your Biotechâs Runway
The date never changed. But the scope moved. If nothing changes after it, it was just a lab update. shared, milestone-driven roadmap tied to strategic decisions, not just scientific deliverables, momentum changes
- The Hidden Operating Cadence Thatâs Actually Driving Your Biotech
And until you see it, you canât change it. What must change? What deserves escalation? â A stable cadence doesnât eliminate surprise.
- Why âDisplacementâ Misleads You: Allosteric Binding Demystified
Session, Youâll Gain: â A clear explanation of why allosteric modulators donât displace ligandsâthey change Youâre no longer tracking the same protein speciesâand that changes everything.
- How System-Level GPCR Thinking Prevents Discovery Failures
Johannes Broichhagen Reliable imaging tools change how researchers see receptor behavior. specificity, relevance, and assay confidence Read the full HCS feature ⤠Why System-Level GPCR Thinking Changes
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
There are only 5 spots left for our upcoming courses, so seize the chance to learn from the best in announced the winners of its Transforming Cancer Therapeutics grant, which focuses on developing life-changing
- How Early Strategic Decision Making Creates Alignment and Better Results
They only feel the consequences months later, when it is hard to change momentum. đ This article is Why Results Appear Too Late to Change the Outcome đ Most teams focus on results because results feel underlying strategy is sound. đ When early strategic decision-making creates alignment, something changes
- Inverse Agonists, Lymphatic Fixes & β-arrestin Tricks
This week brings sharp new insights into how minor changes in ligand structure can flip GPCR function
- đ° GPCR Weekly News, April 29 to May 5, 2024
announcements in todayâs episode, so join us in this celebration and be the first to know about all the changes
- When Pain Becomes a Catalyst: How Personal Experience Redefined One Scientistâs Mission
But everything changed when his recurring pain â and the rigid protocols around opioid prescription â
- First AMA of 2026: GPCR Pharmacology, Biased Signaling & Mechanistic Clarity
definitive during early screening can shift as assay systems, receptor expression levels, or kinetics change




























